347 related articles for article (PubMed ID: 9112654)
1. Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta.
Moniwa N
Pol J Pharmacol; 1996; 48(2):215-20. PubMed ID: 9112654
[TBL] [Abstract][Full Text] [Related]
2. Role of activated protein C in facilitating basement membrane invasion by tumor cells.
Kobayashi H; Moniwa N; Gotoh J; Sugimura M; Terao T
Cancer Res; 1994 Jan; 54(1):261-7. PubMed ID: 8261450
[TBL] [Abstract][Full Text] [Related]
3. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
6. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 by grape seed proanthocyanidin extract.
Sandra D; Radha M; Harishkumar M; Yuichi N; Sayuri O; Masugi M
Phytomedicine; 2010 Jan; 17(1):42-6. PubMed ID: 19640694
[TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
9. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.
Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC
Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829
[TBL] [Abstract][Full Text] [Related]
10. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
11. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
[TBL] [Abstract][Full Text] [Related]
14. The urokinase plasminogen activator (uPA) system in uterine natural killer cells in the placental bed during early pregnancy.
Naruse K; Lash GE; Bulmer JN; Innes BA; Otun HA; Searle RF; Robson SC
Placenta; 2009 May; 30(5):398-404. PubMed ID: 19272641
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
16. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
17. Enhanced PAI-1 levels from early second trimester and during labour and plasminogen activators in normal pregnancy.
Koh SC; Anandakumar C; Biswas A; Fong YF
Thromb Haemost; 2002 Jan; 87(1):175-6. PubMed ID: 11858184
[No Abstract] [Full Text] [Related]
18. Placenta and myometrium--the two main sources of fibrinolytic components during pregnancy.
Uszyński M; Maciejewski K; Uszyński W; Kuczyński J
Gynecol Obstet Invest; 2001; 52(3):189-93. PubMed ID: 11598362
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor--no evidence for a cofactor role of protein S.
de Fouw NJ; de Jong YF; Haverkate F; Bertina RM
Thromb Haemost; 1988 Oct; 60(2):328-33. PubMed ID: 2975409
[TBL] [Abstract][Full Text] [Related]
20. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]